carbamates and encorafenib

carbamates has been researched along with encorafenib in 110 studies

Research

Studies (110)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	44 (40.00)	24.3611
2020's	66 (60.00)	2.80

Authors

Authors	Studies
Anforth, RM; Carlos, GR; Chou, S; Fernandez-Peñas, P; Scolyer, RA	1
Deuker, MM; Marsh Durban, V; McMahon, M; Phillips, WA	1
Dummer, R; Galliker, NA; Goldinger, SM; Kamarashev, J; Murer, C	1
Bi, X; Cheng, W; Gong, P; Jiang, K; Li, Z; Lin, G; Liu, J; Meng, S; Piao, Y; Song, F; Song, Z; Zhao, Y; Zhu, X	1
Adelmann, CH; Bansal, V; Ching, G; Du, L; Lee, W; Liang, R; Pence, LJ; Saporito, RC; Tsai, KY	1
Beijnen, JH; Rood, JJM; Rosing, H; Schellens, JHM; Sparidans, RW	1
Aractingi, S; Avril, MF; Boitier, F; Boulinguez, S; Chanal, J; Deilhes, F; Dupin, N; Guégan, S; Kramkimel, N; Meyer, N; Regnier-Rosencher, E; Vanhaecke, C	1
Beasley, G; Rossfeld, K; Salama, AK; Turner, MC; Tyler, D	1
Avsar, E; Bendell, JC; Chatterjee, A; Delord, JP; Demuth, T; Elez, E; Eskens, FALM; Faris, JE; Jaeger, S; Lenz, HJ; Lolkema, MP; Maharry, K; Schellens, JHM; Schuler, M; Sharma, S; Spreafico, A; Tabernero, J; Tan, E; van Geel, RMJM; Wainberg, ZA; Yaeger, R; Yamada, Y; Yoshino, T	1
Avan, A; Bahrami, A; Ferns, GA; Hassanian, SM; Hesari, A; Khazaei, M	1
Daud, A; Tsai, K	1
Frimat, M; Gnemmi, V; Hazzan, M; Lionet, A; Maanaoui, M; Noël, C; Provot, F; Saint-Jacques, C	1
Flaherty, K	1
Alaibac, M; Chiarion Sileni, V; Frigo, AC; Russo, I; Zorzetto, L	1
Dippel, E; Gutzmer, R; Herbst, R; Kreuter, A; Mohr, P; Okoye, S; Pföhler, C; Satzger, I; Schadendorf, D; Schaper-Gerhardt, K; Sucker, A; Terheyden, P; Ugurel, S; Ulrich, J; Utikal, JS	1
Dummer, R; Koelblinger, P; Thuerigen, O	1
Arance, AM; Boada, A; Carrera, C; Chavez-Bourgeois, MM; Fernández-Sartorio, C; García-Herrera, A; Manzano, JL; Ruiz Ares, GJ	1
Grob, JJ	1
Arance, A; Ascierto, PA; Chiarion-Sileni, V; de Groot, JWB; Dummer, R; Dutriaux, C; Flaherty, KT; Garbe, C; Gogas, HJ; Gutzmer, R; Krajsova, I; Liszkay, G; Loquai, C; Mandala, M; Moutouh-de Parseval, LA; Pickard, MD; Robert, C; Sandor, V; Schadendorf, D; Yamazaki, N	1
Sidaway, P	1
Chen, J; Cohen, P; Hoffman, AR; Hu, JF; Kim, SJ; Kuehnemann, C; Mehta, HH; Wan, J	1
Shirley, M	1
Anastasopoulou, A; Diamantopoulos, PT; Gogas, H; Papaxoinis, G; Stoungioti, S	1
Martin-Liberal, J	1
Arance, A; Ascierto, PA; Chiarion Sileni, V; de Groot, JWB; Dummer, R; Dutriaux, C; Flaherty, KT; Garbe, C; Gogas, HJ; Gutzmer, R; Krajsova, I; Liszkay, G; Loquai, C; Mandala, M; Moutouh-de Parseval, LA; Pickard, MD; Robert, C; Sandor, V; Schadendorf, D; Yamazaki, N	1
Burton, NC; Cyran, CC; Eschbach, RS; Heimer, M; Hirner-Eppeneder, H; Kazmierczak, PM; Keinrath, G; Reiser, MF; Ricke, J; Schneider, MJ; Solyanik, O; Todica, A	1
Barysch, M; Cheng, PF; Conrad, S; Dummer, R; Galliker, N; Goldinger, SM; Graf, NP; Koelblinger, P; Mangana, J	1
Robert, C	1
Ascierto, PA; Festino, L; Trojaniello, C; Vanella, V	1
Benzaquen, M; Berbis, P; Bonnet, N; Brue, A; Default, A; Delaporte, E; Koeppel, MC	1
Christy-Bittel, J; Ciardiello, F; Cuyle, PJ; Desai, J; Elez, E; Fakih, M; Gollerkeri, A; Grothey, A; Huijberts, S; Kopetz, S; Maharry, K; Montagut, C; Peeters, M; Sandor, V; Schellens, JHM; Tabernero, J; Van Cutsem, E; Wasan, H; Yaeger, R; Yoshino, T	1
Livingstone, E	1
Rose, AAN	1
Li, J; Li, X	1
Aebersold, R; Bileck, A; Chatziisaak, TP; Cheng, PF; Dummer, R; Eichhoff, O; Freiberger, SN; Gerner, C; Guenova, E; Irmisch, A; Knapp, B; Kunstfeld, R; Leitner, A; Levesque, MP; Mangana, J; Mohr, T; Paulitschke, P; Paulitschke, V; Pehamberger, H; Saulite, I; Stephan, J; Zila, N	1
Arance, A; Ascierto, PA; de Groot, JWB; Dummer, R; Dutriaux, C; Flaherty, KT; Garbe, C; Gogas, HJ; Gollerkeri, A; Gutzmer, R; Krajsova, I; Liszkay, G; Loquai, C; Mandala, M; Pickard, MD; Robert, C; Schadendorf, D; Sileni, VC; Yamazaki, N	1
Assi, T; Farhat, F; Kattan, C; Kattan, J	1
Bycroft, R; Ngo, P	1
Anderson, L; Arkenau, HT; Braun, M; Calvo Ferrandiz, A; Christy-Bittel, J; Ciardiello, F; Dekervel, J; Desai, J; Elez, E; Garcia-Alfonso, P; Gollerkeri, A; Grothey, A; Guo, C; Guren, TK; Hong, YS; Keir, C; Kim, TW; Kopetz, S; Krishnan, A; Lonardi, S; Loupakis, F; Maharry, K; Morris, V; Orlov, S; Pfeiffer, P; Pickard, M; Sandor, V; Schellens, JHM; Steeghs, N; Tabernero, J; Tarpgaard, LS; Van Cutsem, E; Wasan, H; Yaeger, R; Yoshino, T	1
Killock, D	1
Gunjur, A	1
Amaria, RN; Amin, A; Davies, MA; Davis, JM; Diab, A; Glitza, IC; Holbrook, K; Lutzky, J; Patel, SP; Tawbi, H	1
Arqués, O; Barriuso, J; Capdevila, J; Caratù, G; Esteller, M; Garcia-Carbonero, R; Hernández Mora, JR; Hernández-Losa, J; Hernando, J; Jimenez-Fonseca, P; Landolfi, S; Lopez Lopez, C; Mancuso, FM; Martínez-Cardús, A; Matito, J; Matos, I; Palmer, HG; Paolo, N; Tabernero, J; Vivancos, A	1
Fadul, CE; Gentzler, RD; Hall, RD; McLoughlin, EM; Patel, SH	1
Carr, MJ; Eroglu, Z; Sun, J; Zager, JS	1
Chandrasekharan, C; Kamatham, S; Kasi, PM; Shahjehan, F	1
Arance, A; Ascierto, PA; de Groot, JWB; Dummer, R; Flaherty, KT; Garbe, C; Gogas, HJ; Gollerkeri, A; Gutzmer, R; Krajsova, I; Liszkay, G; Loquai, C; Mandala, M; Pickard, MD; Robert, C; Schadendorf, D	1
Limmer, A; Robare, S; Swali, R	1
Specenier, P	1
Sharma, V; Vanidassane, I	1
Prasad, V	1
Pietrantonio, F	1
Grothey, A; Kopetz, S; Tabernero, J	1
Aiba, S; Amagai, R; Fujimura, T; Hashimoto, A; Kambayashi, Y; Ohuchi, K; Sato, Y; Tanita, K	1
Matsudate, Y	1
Ascierto, PA; Carlino, MS; Dummer, R; Elez, E; Lebbé, C; Patel, S; Pickard, MD; Sandor, V; Siena, S; Sullivan, RJ; Tan, DSW; Weber, J; Wollenberg, L	1
Eroglu, Z; Ismail, S; Okten, IN; Withycombe, BM	1
Forchhammer, S; Forschner, A; Garbe, C; Lang, N; Schaller, M; Schinaia, CG; Wolfsperger, F	1
Leng, T; Li, AS; Liao, YJ; Nagpal, S	1
Indini, A; Mandalà, M	1
Anbar, HS; El-Gamal, MI; Jeon, HR; Kwon, D; Lee, BS; Oh, CH; Tarazi, H	1
Byron, Y; Nott, L; Shackleton, M	1
Ahlström, H; Botling, J; Dahlstrand, H; Koliadi, A; Öberg, K; Tholander, B; Ullenhag, GJ; Von Heideman, A	1
Boilève, A; Samalin, E	1
Batko, S	1
Calapre, L; Gray, ES; McEvoy, A; Meniawy, TM; Millward, M; Pereira, M; Warburton, L; Ziman, M	1
Aiba, S; Amagai, R; Fujimura, T; Fujisawa, Y; Furudate, S; Hashimoto, A; Ito, T; Kambayashi, Y; Kato, H; Kunimoto, K; Maekawa, T; Matsushita, S; Muto, Y; Nakamura, Y; Ohuchi, K; Yamamoto, Y; Yoshino, K	1
Bernards, R; Boelens, MC; Huijberts, SCFA; Opdam, FL	1
Enzler, F; Feichtner, A; Fleischmann, J; Hartl, M; Huber, RG; Mayrhofer, JE; Ogris, E; Raffeiner, A; Röck, R; Schneider, R; Stefan, E; Torres-Quesada, O; Troppmair, J; Tschaikner, P	1
Dedorath, J; Delgado, J; Enzmann, H; Fuerstenau, U; Hausmann, S; Koenig, J; Pignatti, F; Stock, T; Trullas, A	1
Huntington, SF; Lacy, J; O'Hara, M; Patel, KK; Stein, S	1
Arkenau, HT; Christy-Bittel, J; Ciardiello, F; Desai, J; Elez, E; Garcia-Alfonso, P; Gollerkeri, A; Grothey, A; Guren, TK; Hong, YS; Kopetz, S; Loupakis, F; Maharry, K; Steeghs, N; Tabernero, J; Van Cutsem, E; Wasan, H; Yaeger, R; Yoshino, T	1
Ding, D; Hu, H; Huang, J; Li, S; Zhu, Y	1
Lankheet, NAG; Meussen, E; Mian, P; Piersma, D	1
Duong, JP; Gallois, C; Karras, A; Lazareth, H; Stammler, R; Taieb, J; Thervet, E	1
Baric, L; Cantagrel, A; Di Palma, M; Ederhy, S; Paques, M; Perlemuter, G; Sibaud, V	1
Spagnolo, F	1
Comet, A; Denis, D; Ramtohul, P	1
Al-Salama, ZT	1
Furukawa, Y; Hara, S; Hiramoto, N; Ishii, J; Ishikawa, T; Nagata, K; Nannya, Y; Ogawa, S; Wada, F; Yamashita, D	1
Al-Kindi, S; Barnholtz-Sloan, JS; de Lima, M; Dowlati, A; Fradley, MG; Guha, A; Gutierrez, JM; Jain, C; Jain, P; Lenihan, D; Oliveira, GH	1
Hanft, S; Khullar, K; Mehnert, JM; Weiner, JP	1
El-Khoury, R; Gallois, C; Garinet, S; Hafliger, E; Louafi, S; Taieb, J; Zaanan, A	1
Arance, A; Ascierto, PA; Dummer, R; Dutriaux, C; Flaherty, KT; Garbe, C; Gogas, H; Gollerkeri, A; Gutzmer, R; Jan de Willem, G; Krajsová, I; Liszkay, G; Loquai, C; Mandalà, M; Murris, J; Queirolo, P; Robert, C; Schadendorf, D; Sellier, AT; Sileni, VC; Suissa, J; Yamazaki, N	1
Cullen, GD; Finnes, HD; Markovic, SN; Volcheck, GW	1
Ardizzoni, A; D'Errico, A; Di Federico, A; Gelsomino, F; Grilli, G; Salvagni, S; Tardio, ML	1
Bonetti, A; Giuliani, J; Mantoan, B	1
Anghelone, A; Ardito, F; Basso, M; Bensi, M; Calegari, MA; Camarda, F; Carbone, C; Giuliante, F; Martini, M; Pozzo, C; Ribelli, M; Salvatore, L; Stefano, BD; Tortora, G; Vellone, M; Vivolo, R	1
Broudin, C; Gallois, C; Garinet, S; Karoui, M; Sabouret, A; Taieb, J; Zaanan, A	1
Christy-Bittel, J; Ciardiello, F; Desai, J; Gollerkeri, A; Grothey, A; Kopetz, S; Maharry, K; Tabernero, J; Trevino, TL; Van Cutsem, E; Velez, L; Wasan, H; Yaeger, R; Yoshino, T	1
Kono, M; Noto, M; Sato, T; Yamada, M	1
Fakih, M; Ji, J; Wang, C	1
Alharbi, HO; Barton, PJ; Chothani, SP; Clerk, A; Cook, SA; Cooper, STE; Cull, JJ; Felkin, LE; Fuller, SJ; Glennon, PE; Hardyman, MA; Leonard, SJ; Markou, T; McTiernan, CF; Meijles, DN; Rackham, OJL; Rojas, M; Sembrat, JC; Shaw, SW; Sheppard, MN; Sugden, PH; Vanezis, K	1
Ascierto, PA; Brill, K; Dummer, R; McKean, M; Panella, T; Pietro, AD; Polli, A; Ribas, A; Robert, C; Santos, ES; Schadendorf, D; Sullivan, RJ	1
Hashimoto, Y; Kadono, T; Miyagaki, T; Miyano, K; Omori, R	1
Antista, M; Boccaccino, A; Bourgeois, V; Cremolini, C; El-Khoury, R; Evesque, L; Gallois, C; Hafliger, E; Lapeyre-Prost, A; Lecomte, T; Lonardi, S; Perret, A; Pilla, L; Salati, M; Salvatore, L; Scartozzi, M; Soularue, E; Taieb, J; Tougeron, D; Vaillant, JN	1
Amano, H; Miura, S; Onishi, M; Watabe, D	1
Alfallouji, Y; Borysiewicz, C; Bunker, CB; Calonje, E; Hodgkinson, T; Perrett, CM; Sidwell, RU; Spencer, A; Wasan, H; Watchorn, R	1
Arkenau, HT; Belani, A; Ciardiello, F; Desai, J; Garcia-Alfonso, P; Grothey, A; Guren, TK; Hong, YS; Kopetz, S; Loupakis, F; Steeghs, N; Tabernero, J; Van Cutsem, E; Wasan, H; Yaeger, R; Yoshino, T; Zhang, X	1
Antista, M; Antonuzzo, L; Bensi, M; Boccaccino, A; Borelli, B; Cremolini, C; Crespi, V; Giampieri, R; Giordano, M; Intini, R; Libertini, M; Lonardi, S; Moretto, R; Noto, C; Noto, L; Parisi, A; Passardi, A; Persano, M; Puccini, A; Rihawi, K; Rossini, D; Roviello, G; Salati, M; Tamberi, S; Zichi, C	1
Ciccolini, J; Milano, G	1
Di Guardo, L	1
Biedermann, T; Claussen, CS; Eberlein, B; Evers, B; Keshmiri, M; Li, L; Mathes, S; Posch, C	1
Elez, E; Ros, J	1
Berardi, R; Corrie, P; Guidoboni, M; Kolovos, S; Laramée, P; Macabeo, B; Meyer, N; Schlueter, M; Trouiller, JB	1
Agocs, GR; Bastian, S; Eisterer, W; Fenchel, K; Fritsch, R; Fuxius, S; Gerger, A; Greil, R; Koeberle, D; Maas, C; Modest, DP; Reichenbach, F; Sanoyan, DA; Schwager, M; Uhlig, J; VON DER Heyde, E; Weide, R; Welslau, M	1
Chu, EY; Clark, A; Godse, R	1
Akasaka, E; Mikami, H; Nakano, H; Sawamura, D	1

Reviews

20 review(s) available for carbamates and encorafenib

Article	Year
Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment? Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:5 Topics: Benzamides; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Piperidines; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyridines; Skin Neoplasms; Sulfonamides; Thiazoles	2017
The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer. Journal of cellular physiology, 2018, Volume: 233, Issue:3 Topics: Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cinnamates; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Indoles; MAP Kinase Kinase Kinases; Oximes; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib	2018
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. The oncologist, 2017, Volume: 22, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Carbamates; Fever; Humans; Imidazoles; Indoles; Melanoma; Mitogen-Activated Protein Kinase Kinases; Oximes; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Diseases; Sulfonamides; Vemurafenib	2017
Development of encorafenib for BRAF-mutated advanced melanoma. Current opinion in oncology, 2018, Volume: 30, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Clinical Trials, Phase III as Topic; Humans; Melanoma; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Sulfonamides	2018
Encorafenib and Binimetinib: First Global Approvals. Drugs, 2018, Volume: 78, Issue:12 Topics: Benzimidazoles; Carbamates; Drug Approval; Humans; MAP Kinase Kinase Kinases; Melanoma; Molecular Structure; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Treatment Outcome; United States	2018
[What's new in oncodermatology?] Annales de dermatologie et de venereologie, 2018, Volume: 145 Suppl 7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Benzimidazoles; Biomarkers, Tumor; Carbamates; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Dermatology; Humans; Melanoma; Skin Neoplasms; Sulfonamides; Survival Analysis	2018
Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Expert review of clinical pharmacology, 2019, Volume: 12, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Disease-Free Survival; Humans; Melanoma; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides	2019
Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma. Drugs of today (Barcelona, Spain : 1998), 2019, Volume: 55, Issue:4 Topics: Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides	2019
An evaluation of encorafenib for the treatment of melanoma. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides	2020
Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer. Drugs of today (Barcelona, Spain : 1998), 2019, Volume: 55, Issue:11 Topics: Benzimidazoles; Carbamates; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Humans; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; Sulfonamides	2019
An overview of binimetinib for the treatment of melanoma. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Clinical Trials as Topic; GTP Phosphohydrolases; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Melanoma; Membrane Proteins; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides	2020
Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients. Expert opinion on drug safety, 2020, Volume: 19, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Melanoma; Point Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Survival Rate	2020
Current perspectives on the treatment of BRAF mutated colorectal carcinoma. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2020,Spring, Volume: 33, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides	2020
The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy. ESMO open, 2021, Volume: 6, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Humans; Mutation; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Sulfonamides	2021
Encorafenib (Braftovi) for metastatic colorectal cancer. The Medical letter on drugs and therapeutics, 2021, 01-25, Volume: 63, Issue:1616 Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Proto-Oncogene Proteins B-raf; Sulfonamides	2021
[Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma]. Bulletin du cancer, 2021, Volume: 108, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Carbamates; Drug Combinations; Humans; Imidazoles; Melanoma; Mitogen-Activated Protein Kinase Kinases; Mutation; Oximes; Piperidines; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Sulfonamides; Vemurafenib	2021
Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation. Drugs, 2021, Volume: 81, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Drug Interactions; Humans; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis	2021
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO open, 2021, Volume: 6, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides	2021
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable Future oncology (London, England), 2022, Volume: 18, Issue:17 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Neoplasms, Second Primary; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Skin Neoplasms; Sulfonamides	2022
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis. Cancer treatment reviews, 2022, Volume: 110 Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Neoplasms, Second Primary; Network Meta-Analysis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib	2022

Trials

12 trial(s) available for carbamates and encorafenib

Article	Year
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic Cancer discovery, 2017, Volume: 7, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Thiazoles	2017
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. The Lancet. Oncology, 2018, Volume: 19, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carbamates; Female; Humans; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Time Factors; Vemurafenib; Young Adult	2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology, 2018, Volume: 19, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carbamates; Disease Progression; Female; Genetic Predisposition to Disease; Humans; Male; Melanoma; Middle Aged; Mutation; Phenotype; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Time Factors; Vemurafenib; Young Adult	2018
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 06-10, Volume: 37, Issue:17 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Folic Acid; Humans; Irinotecan; Male; Middle Aged; Mutation; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Sulfonamides; Survival Rate	2019
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. European journal of cancer (Oxford, England : 1990), 2019, Volume: 119 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Fatigue; Female; Humans; Incidence; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinases; Mutation; Nausea; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib; Vomiting	2019
Encorafenib, Binimetinib, and Cetuximab in The New England journal of medicine, 2019, 10-24, Volume: 381, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Disease Progression; Electrocorticography; Female; Humans; Intention to Treat Analysis; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides; Survival Analysis	2019
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. European journal of cancer (Oxford, England : 1990), 2020, Volume: 126 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Diarrhea; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Mutation; Nausea; Outcome Assessment, Health Care; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib; Vomiting	2020
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 10-01, Volume: 26, Issue:19 Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides	2020
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 02-01, Volume: 39, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins B-raf; Standard of Care; Sulfonamides; Survival Rate	2021
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). European journal of cancer (Oxford, England : 1990), 2021, Volume: 152 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Female; Humans; Male; Melanoma; Middle Aged; Mutation; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Quality of Life; Skin Neoplasms; Sulfonamides; Vemurafenib; Young Adult	2021
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. ESMO open, 2022, Volume: 7, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Mutation; Patient Reported Outcome Measures; Proto-Oncogene Proteins B-raf; Quality of Life; Sulfonamides	2022
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ESMO open, 2022, Volume: 7, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Humans; Proto-Oncogene Proteins B-raf; Sulfonamides	2022

Other Studies

78 other study(ies) available for carbamates and encorafenib

Article	Year
Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma. Melanoma research, 2015, Volume: 25, Issue:1 Topics: Antineoplastic Agents; Carbamates; Dermatology; Dermoscopy; Humans; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Nevus, Pigmented; Pigmentation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides	2015
PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer discovery, 2015, Volume: 5, Issue:2 Topics: Animals; Carbamates; Cell Line, Tumor; Cell Proliferation; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Melanoma; Melanoma, Experimental; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Random Allocation; Sulfonamides; Thiazoles	2015
Drug combo beneficial in colorectal cancer. Cancer discovery, 2015, Volume: 5, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Sulfonamides; Thiazoles	2015
Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor. European journal of dermatology : EJD, 2015, Volume: 25, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Imidazoles; Male; Melanoma; Mitogen-Activated Protein Kinases; Oximes; Panniculitis; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Neoplasms; Sulfonamides	2015
Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer letters, 2016, Jan-28, Volume: 370, Issue:2 Topics: Autophagy; Carbamates; Cell Line, Tumor; Cellular Senescence; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Dyrk Kinases; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; MAP Kinase Signaling System; Melanoma; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Retinoblastoma Protein; Sulfonamides; TOR Serine-Threonine Kinases	2016
Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget, 2016, May-24, Volume: 7, Issue:21 Topics: Apoptosis; Carbamates; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Enzyme Activation; Heterocyclic Compounds, 2-Ring; Humans; Imidazoles; Indoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib	2016
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2016, Oct-15, Volume: 1033-1034 Topics: Administration, Oral; Adult; Afatinib; Aged; Aged, 80 and over; Calibration; Carbamates; Chromatography, Liquid; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry	2016
BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients. The British journal of dermatology, 2017, Volume: 177, Issue:4 Topics: Adult; Antineoplastic Agents; Carbamates; Drug Substitution; Humans; Imidazoles; Indoles; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Oximes; Proto-Oncogene Proteins B-raf; Retrospective Studies; Skin Neoplasms; Sulfonamides; Vemurafenib; Young Adult	2017
Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma: A case report. Medicine, 2017, Volume: 96, Issue:25 Topics: Antineoplastic Agents; Benzimidazoles; Carbamates; Female; Glomerulonephritis; Humans; Kidney; Lung Neoplasms; MAP Kinase Kinase Kinases; Melanoma; Middle Aged; Protein Kinase Inhibitors; Sulfonamides; Vasculitis	2017
In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma. Clinical advances in hematology & oncology : H&O, 2017, Volume: 15, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides	2017
A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience. European journal of dermatology : EJD, 2017, Oct-01, Volume: 27, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Imidazoles; Indoles; MAP Kinase Kinase Kinases; Melanoma; Melanoma, Cutaneous Malignant; Mutation; Oximes; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Diseases; Skin Neoplasms; Sulfonamides; Vemurafenib	2017
PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. European journal of cancer (Oxford, England : 1990), 2018, Volume: 88 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carbamates; Female; Humans; Imidazoles; Indoles; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Oximes; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Retrospective Studies; Sulfonamides; Treatment Outcome; Vemurafenib; Young Adult	2018
Aged-looking skin and encorafenib: an adverse event of BRAF inhibitors. Melanoma research, 2018, Volume: 28, Issue:2 Topics: Adult; Carbamates; Humans; Male; Melanoma; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin; Skin Aging; Skin Neoplasms; Sulfonamides	2018
Is there any interest in a new BRAF-MEK inhibitor combination in melanoma? The Lancet. Oncology, 2018, Volume: 19, Issue:5 Topics: Benzimidazoles; Carbamates; Humans; Melanoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib	2018
Encorafenib - a new agent for advanced-stage disease. Nature reviews. Clinical oncology, 2018, Volume: 15, Issue:6 Topics: Benzimidazoles; Carbamates; Humans; Melanoma; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib	2018
Mitochondrial peptides modulate mitochondrial function during cellular senescence. Aging, 2018, Jun-10, Volume: 10, Issue:6 Topics: Carbamates; Cells, Cultured; Cellular Senescence; DNA Copy Number Variations; DNA, Mitochondrial; Fibroblasts; Gene Expression Regulation; Humans; Mitochondria; Mitochondrial Proteins; Sulfonamides	2018
Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma. Melanoma research, 2018, Volume: 28, Issue:6 Topics: Aged, 80 and over; Benzimidazoles; Carbamates; Female; Humans; Melanoma; Protein Kinase Inhibitors; Sulfonamides; Uveomeningoencephalitic Syndrome	2018
Encorafenib plus binimetinib: an embarrassment of riches. The Lancet. Oncology, 2018, Volume: 19, Issue:10 Topics: Benzimidazoles; Carbamates; Embarrassment; Humans; Melanoma; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib	2018
Integrin-targeted quantitative optoacoustic imaging with MRI correlation for monitoring a BRAF/MEK inhibitor combination therapy in a murine model of human melanoma. PloS one, 2018, Volume: 13, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cell Line, Tumor; Humans; Integrin alphaVbeta3; Magnetic Resonance Imaging; Melanoma; Mice; Mice, Nude; Molecular Imaging; Mutation; Photoacoustic Techniques; Proto-Oncogene Proteins B-raf; Sulfonamides; Treatment Outcome; Xenograft Model Antitumor Assays	2018
The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:4 Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Drug Eruptions; Female; Hand-Foot Syndrome; Humans; Keratosis; Male; Melanoma; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides	2019
Desensitization protocol for angio-oedema induced by encorafenib in a patient with metastatic melanoma. Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:7 Topics: Carbamates; Edema; Humans; Imidazoles; Melanoma; Oximes; Sulfonamides	2019
Evaluation of cutaneous adverse events of encorafenib and binimetinb: COMMENT on article by Graf et al. Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:4 Topics: Benzimidazoles; Carbamates; Fibrosarcoma; Humans; Melanoma; Sulfonamides	2019
Encorafenib inhibits migration, induces cell cycle arrest and apoptosis in colorectal cancer cells. Molecular and cellular biochemistry, 2019, Volume: 459, Issue:1-2 Topics: Apoptosis; Carbamates; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Humans; Sulfonamides	2019
Proteomic identification of a marker signature for MAPKi resistance in melanoma. The EMBO journal, 2019, 08-01, Volume: 38, Issue:15 Topics: Adult; Aged; Carbamates; Cell Adhesion; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Proteins; Male; Melanoma; Middle Aged; Protein Interaction Maps; Protein Kinase Inhibitors; Proteomics; RNA-Binding Proteins; Sequence Analysis, RNA; Sulfonamides; Survival Analysis; Up-Regulation; Vemurafenib	2019
Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report. Anti-cancer drugs, 2019, Volume: 30, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Drug Resistance, Neoplasm; Humans; Lymph Node Excision; Male; MAP Kinase Kinase 1; Margins of Excision; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib	2019
Encorafenib and binimetinib for the treatment of BRAF-mutated metastatic melanoma in the setting of combined hepatic and renal impairment. BMJ case reports, 2019, Sep-16, Volume: 12, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Proto-Oncogene Proteins B-raf; Renal Insufficiency; Skin Neoplasms; Sulfonamides	2019
BEACON of hope in BRAF Nature reviews. Clinical oncology, 2019, Volume: 16, Issue:12 Topics: Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Proto-Oncogene Proteins B-raf; Sulfonamides	2019
Targeted therapy for BRAF-mutant colorectal cancer. The Lancet. Oncology, 2019, Volume: 20, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Humans; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome	2019
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. Cancer, 2020, 02-01, Volume: 126, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Carbamates; Female; Humans; Male; MAP Kinase Kinase Kinases; Melanoma; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides	2020
Epigenetic Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 02-15, Volume: 26, Issue:4 Topics: Animals; Carbamates; Carcinoma, Neuroendocrine; Cetuximab; Colonic Neoplasms; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Treatment Outcome; Xenograft Model Antitumor Assays	2020
Clinical and Radiographic Response of Leptomeningeal and Brain Metastases to Encorafenib and Binimetinib in a Patient With BRAF V600E-Mutated Lung Adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:12 Topics: Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Carbamates; Disease Progression; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides	2019
Multiple Pigmented Lesions of the Breast Following Ipsilateral Breast Carcinoma. The American journal of medicine, 2020, Volume: 133, Issue:8 Topics: Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Carbamates; Female; Humans; Mastectomy; Mastectomy, Segmental; Melanoma; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Neoplasms, Unknown Primary; Radiotherapy; Skin Neoplasms; Sulfonamides	2020
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. The New England journal of medicine, 2020, 02-27, Volume: 382, Issue:9 Topics: Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Proto-Oncogene Proteins B-raf; Sulfonamides	2020
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. The New England journal of medicine, 2020, 02-27, Volume: 382, Issue:9 Topics: Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Proto-Oncogene Proteins B-raf; Sulfonamides	2020
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. The New England journal of medicine, 2020, 02-27, Volume: 382, Issue:9 Topics: Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Proto-Oncogene Proteins B-raf; Sulfonamides	2020
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. Reply. The New England journal of medicine, 2020, 02-27, Volume: 382, Issue:9 Topics: Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Proto-Oncogene Proteins B-raf; Sulfonamides	2020
Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib. The Journal of dermatology, 2020, Volume: 47, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Drug Resistance, Neoplasm; Female; Fever; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Nivolumab; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Treatment Outcome	2020
Case of inflammatory arthritis induced by encorafenib and binimetinib in a patient with melanoma. The Journal of dermatology, 2020, Volume: 47, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Arthritis; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides	2020
Preclinical discovery and clinical development of encorafenib for the treatment of melanoma. Expert opinion on drug discovery, 2020, Volume: 15, Issue:12 Topics: Animals; Carbamates; Drug Development; Drug Discovery; Drug Evaluation, Preclinical; Humans; Melanoma; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides	2020
Toxic epidermal necrolysis in a melanoma patient under targeted therapy with encorafenib and binimetinib. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2020, Volume: 18, Issue:10 Topics: Benzimidazoles; Carbamates; Humans; Melanoma; Stevens-Johnson Syndrome; Sulfonamides	2020
Rapid Fluctuation of Subretinal Fluid on Encorafenib and Binimetinib. Retina (Philadelphia, Pa.), 2020, Volume: 40, Issue:11 Topics: Antineoplastic Agents; Astrocytoma; Benzimidazoles; Brain Neoplasms; Carbamates; Female; Humans; MAP Kinase Kinase Kinase 1; MAP Kinase Kinase Kinase 2; Middle Aged; Proto-Oncogene Proteins B-raf; Retinal Diseases; Subretinal Fluid; Sulfonamides	2020
Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies. Journal of enzyme inhibition and medicinal chemistry, 2020, Volume: 35, Issue:1 Topics: Antineoplastic Agents; Carbamates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Molecular Dynamics Simulation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quantitative Structure-Activity Relationship; Sorafenib; Sulfonamides; Thiazoles; Vemurafenib	2020
Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass. Melanoma research, 2020, Volume: 30, Issue:6 Topics: Acute Disease; Benzimidazoles; Carbamates; Female; Humans; Melanoma; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Tumor Lysis Syndrome	2020
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma. Upsala journal of medical sciences, 2020, Volume: 125, Issue:4 Topics: Antineoplastic Agents; Benzimidazoles; Bevacizumab; CA-125 Antigen; Carbamates; Carboplatin; Cystadenocarcinoma, Serous; Disease Progression; Everolimus; Female; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; MAP Kinase Kinase 1; Medroxyprogesterone; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Oximes; Paclitaxel; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Recurrence; Sulfonamides; Tamoxifen; Treatment Outcome; Young Adult	2020
[New drug approval: Encorafenib-metastatic colorectal cancers with BRAF V600E mutation after systemic chemotherapy]. Bulletin du cancer, 2020, Volume: 107, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Approval; Humans; Mutation; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Sulfonamides	2020
Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma. Scientific reports, 2020, 11-02, Volume: 10, Issue:1 Topics: Adult; Aged; Carbamates; Circulating Tumor DNA; Disease Progression; Female; Humans; Imidazoles; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasm Recurrence, Local; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib	2020
Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy. The Journal of dermatology, 2021, Volume: 48, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides	2021
Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib. British journal of cancer, 2021, Volume: 124, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carbamates; Cetuximab; Cohort Studies; Colorectal Neoplasms; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Retrospective Studies; Sulfonamides; Thiazoles	2021
Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies. Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49 Topics: A549 Cells; Carbamates; Heterocyclic Compounds, 2-Ring; Humans; Imidazoles; Lung Neoplasms; Mutation; Oximes; Phosphotransferases; Protein Conformation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib	2020
Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer. JAMA network open, 2021, 01-04, Volume: 4, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Markov Chains; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; Quality-Adjusted Life Years; Sulfonamides	2021
Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA. Advances in therapy, 2021, Volume: 38, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Proto-Oncogene Proteins B-raf; Quality-Adjusted Life Years; Sulfonamides; United States	2021
Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report. Anti-cancer drugs, 2021, 06-01, Volume: 32, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Communicable Disease Control; COVID-19; Dose-Response Relationship, Drug; Drug Monitoring; Drug Overdose; Humans; Liver Function Tests; Long QT Syndrome; Male; Medication Therapy Management; Melanoma; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vomiting	2021
Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer. European journal of cancer (Oxford, England : 1990), 2021, Volume: 147 Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Recovery of Function; Risk Factors; Sulfonamides; Treatment Outcome	2021
[Long-term efficacy of encorafenib plus binimetinib combined treatment: case report.] Recenti progressi in medicina, 2021, Volume: 112, Issue:4 Topics: Aged; Benzimidazoles; Carbamates; COVID-19; Drug Combinations; Female; Humans; Melanoma; Skin Neoplasms; Sulfonamides; Time Factors; Treatment Outcome	2021
Kinetics of Punctate Subretinal Deposits in Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy Using En Face Optical Coherence Tomography. Retina (Philadelphia, Pa.), 2021, May-01, Volume: 41, Issue:5 Topics: Acrylonitrile; Adult; Aniline Compounds; Carbamates; Extracellular Signal-Regulated MAP Kinases; Fluorescein Angiography; Fundus Oculi; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Mitogen-Activated Protein Kinases; Retina; Retinal Diseases; Skin Neoplasms; Subretinal Fluid; Sulfonamides; Tomography, Optical Coherence	2021
Dramatic response to encorafenib in a patient with Erdheim-Chester disease harboring the BRAF American journal of hematology, 2021, 08-01, Volume: 96, Issue:8 Topics: Aged, 80 and over; Carbamates; Erdheim-Chester Disease; Female; Humans; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides	2021
Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries. Cancer medicine, 2021, Volume: 10, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Carbamates; Carcinoma, Non-Small-Cell Lung; Cardiotoxicity; Cardiovascular Diseases; Colonic Neoplasms; Cross-Sectional Studies; Female; Heart Failure; Humans; Hypertension; Imidazoles; Lung Neoplasms; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Oximes; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Registries; Regression Analysis; Skin Neoplasms; Sulfonamides; Vemurafenib; Venous Thromboembolism; Young Adult	2021
Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib. Melanoma research, 2021, 08-01, Volume: 31, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Carbamates; Female; Humans; Melanoma; Proto-Oncogene Proteins B-raf; Radiosurgery; Skin Neoplasms; Sulfonamides	2021
Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naive patient for BRAF V600E-mutated metastatic colon cancer. European journal of cancer (Oxford, England : 1990), 2021, Volume: 152 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colonic Neoplasms; ErbB Receptors; Female; Humans; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides; Treatment Outcome	2021
Successful encorafenib desensitization in a patient with recurrent metastatic melanoma. Melanoma research, 2021, 08-01, Volume: 31, Issue:4 Topics: Aged; Carbamates; Female; Humans; Melanoma; Neoplasm Recurrence, Local; Skin Neoplasms; Sulfonamides	2021
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report. Investigational new drugs, 2022, Volume: 40, Issue:1 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Carcinoma, Non-Small-Cell Lung; Colitis; Humans; Lung Neoplasms; Male; Mitogen-Activated Protein Kinase Kinases; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides	2022
Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Humans; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides	2022
Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report. Clinical colorectal cancer, 2021, Volume: 20, Issue:4 Topics: Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Liver; Proto-Oncogene Proteins B-raf; Sulfonamides	2021
Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report. Genes, chromosomes & cancer, 2022, Volume: 61, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carbamates; Cetuximab; Colon; Colorectal Neoplasms; Disease Progression; DNA Methylation; Female; Humans; Immunotherapy; Microsatellite Instability; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides	2022
Switch from dabrafenib/trametinib combination therapy to encorafenib/binimetinib combination therapy with transition of serum lactate dehydrogenase level in melanoma: A case report. Dermatologic therapy, 2022, Volume: 35, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Imidazoles; Lactate Dehydrogenases; Melanoma; Mutation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Neoplasms; Sulfonamides	2022
Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAF Clinical colorectal cancer, 2022, Volume: 21, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides	2022
Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo. The Biochemical journal, 2022, 02-11, Volume: 479, Issue:3 Topics: Animals; Carbamates; Cardiomegaly; Cell Size; Cells, Cultured; Dimerization; Gene Knock-In Techniques; Heart Failure; Humans; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mutation, Missense; Myocytes, Cardiac; Point Mutation; Protein Conformation; Protein Interaction Mapping; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Rats; Rats, Sprague-Dawley; Sulfonamides	2022
Multiple pigmented nevi induced by the combination of encorafenib and cetuximab in a colon cancer patient. The Journal of dermatology, 2022, Volume: 49, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Humans; Nevus, Pigmented; Proto-Oncogene Proteins B-raf; Sulfonamides	2022
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series. European journal of cancer (Oxford, England : 1990), 2022, Volume: 168 Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Mutation; Panitumumab; Proto-Oncogene Proteins B-raf; Retrospective Studies; Sulfonamides	2022
Conjunctival malignant melanoma treated successfully with BRAF inhibitor: encorafenib plus binimetinib. Dermatology online journal, 2022, 01-15, Volume: 28, Issue:1 Topics: Benzimidazoles; Carbamates; Humans; Melanoma; Proto-Oncogene Proteins B-raf; Sulfonamides	2022
Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases. Clinical and experimental dermatology, 2022, Volume: 47, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Exanthema; Humans; Mutation; Nevus, Pigmented; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Rectal Neoplasms; Skin Neoplasms; Sulfonamides	2022
Fewer cetuximab-related skin-toxicities in colorectal cancer patients treated with encorafenib: a Yin and Yang effect of ERK paradoxical activation. Annals of oncology : official journal of the European Society for Medical Oncology, 2022, Volume: 33, Issue:9 Topics: Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Proto-Oncogene Proteins B-raf; Sulfonamides	2022
[Efficacy of the encorafenib + binimetinib combination in a BRAF mutated metastatic melanoma case report]. Recenti progressi in medicina, 2022, Volume: 113, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Melanoma; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides	2022
Phototesting in a case of encorafenib-related photosensitivity. Journal of the European Academy of Dermatology and Venereology : JEADV, 2022, Volume: 36, Issue:11 Topics: Carbamates; Humans; Photosensitivity Disorders; Sulfonamides; Ultraviolet Rays	2022
Overcoming acquired MET amplification after encorafenib-cetuximab in BRAF-V600E mutated colorectal cancer. European journal of cancer (Oxford, England : 1990), 2022, Volume: 172 Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Humans; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides	2022
Retrospective Analysis of Treatment Pathways in Patients With BRAF Anticancer research, 2022, Volume: 42, Issue:10 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Female; Humans; Male; Microsatellite Instability; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Retrospective Studies; Sulfonamides	2022
Diverse cutaneous adverse reactions associated with encorafenib therapy. Dermatology online journal, 2022, 06-15, Volume: 28, Issue:3 Topics: Carbamates; Humans; Sulfonamides	2022
Eruptive melanocytic nevi associated with encorafenib and cetuximab combination therapy. The Journal of dermatology, 2023, Volume: 50, Issue:5 Topics: Carbamates; Cetuximab; Humans; Nevus, Pigmented; Skin Neoplasms	2023